Natera (NASDAQ:NTRA) saw its stock climb over 16% following the release of impressive third-quarter results and an upward revision to its full-year guidance. The genetic testing company reported a loss of $0.26 per share, far better than the anticipated $0.57 loss. Revenue surged 63.9% year-over-year to $439.8 million, significantly surpassing the Street consensus estimate of $361.43 million.
The company processed approximately 775,800 tests during the quarter, a 23.9% increase from the 626,000 tests conducted in the same period last year. Growth was particularly strong in oncology testing, with volumes rising 54.4% year-over-year to 137,100 tests, reflecting robust demand in that segment.
Building on its solid performance, Natera raised its full-year revenue guidance to a range of $1.61 billion to $1.64 billion, up from its previous forecast and above analyst expectations of $1.52 billion. The company also projected positive cash flow of $50 to $75 million for the full year.